ClinicalTrials.gg
CompletedNCT01396447Updated May 1, 2018Results posted

Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

A Phase 2 interventional study of Placebo and Cariprazine in Depression, Bipolar, sponsored by Forest Laboratories. Completed at 88 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-05-01.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
584
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.

Enrollment
Largest of 11
584 · median 234
Started
2011
the only one that year
Phase 2
6 of 11
1 open now
Registered
5th of 11
by date

Among the 11 studies in Bipolar Disorder by AbbVie, this one has the largest enrollment, is the only one that started in 2011, is one of 6 in phase 2, and was the 5th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Bipolar Disorder by AbbVie, or all of them as a file.
02

Study summary

The objective of this study was to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of participants with bipolar depression.

03

Conditions studied

  • Depression, Bipolar

Keywords

  • Bipolar I disorder
  • Bipolar depression
  • Depression
  • Bipolar disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have provided prior to any study specific procedures.
  • Participants currently meeting the , Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder as confirmed by the Structured Clinical Interview (SCID) with a current with a current major depressive episode of at least 4 weeks and not exceeding 12 months in duration.
  • Participants with normal physical examination, laboratory, vital signs, and/or echocardiogram ().
  • Verified previous manic or mixed episode.
  • Participants with a total Hamilton Rating Scale for Depression (HAMD)-17 score ≥ 20.
  • Participants with a HAMD-17 item 1 score ≥ 2.
  • Participants with a Clinical Global Impression of Severity (CGI-S) score ≥ 4.

Exclusion criteria

Exclusion Criteria:

  • Participants with a diagnosis of an axis I disorder other than bipolar I disorder that was the primary focus of treatment within the previous 6 months.
  • Women who are pregnant or breast feeding
  • Participants with Young Mania Rating Scale (YMRS) total score > 10
  • Participants who have dementia, mental retardation, schizophrenia/schizoaffective disorder.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
584 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo orally once a day for 8 weeks.

    Drug: Placebo

  • Experimental
    Cariprazine 0.75 mg

    Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.

    Drug: Cariprazine

  • Experimental
    Cariprazine 1.5 mg

    Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.

    Drug: Cariprazine

  • Experimental
    Cariprazine 3.0 mg

    Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.

    Drug: Cariprazine

Interventions

  • DrugPlacebo

    Placebo was supplied in capsules.

  • Cariprazine was supplied in capsules.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Montgomery-Åsberg Depression Rating Scale Total Score at Week 6

    The Montgomery-Åsberg Depression Rating Scale is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. The scores on the 10 items are summed for a total score that can range from 0 to 60. A higher score indicates greater depression. A negative change score indicates improvement.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Change From Baseline in the Clinical Global Impressions-Severity Total Score at Week 6

    The Clinical Global Impressions-Severity scale is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The participant is rated on a scale from 1 to 7 with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A higher score indicates greater illness. A negative change score indicates improvement.

    Time frame: Baseline to Week 6

07

Results

Posted May 1, 2018

Participant flow

Adult participants with a diagnosis of bipolar I disorder with a current major depressive episode were considered for participation in the study.

Participant flow — Overall Study
MilestonePlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mg
Started148143147146
Received treatment145141146146
Completed10510311794
Not completed43403052
Withdrew: Did not receive treatment3210
Withdrew: Adverse event15121217
Withdrew: Insufficient therapeutic response5524
Withdrew: Protocol violation5237
Withdrew: Withdrawal of consent119415
Withdrew: Lost to follow-up4879
Withdrew: Other miscellaneous reasons0210

Outcome measures

PrimaryChange From Baseline in the Montgomery-Åsberg Depression Rating Scale Total Score at Week 6

The Montgomery-Åsberg Depression Rating Scale is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. The scores on the 10 items are summed for a total score that can range from 0 to 60. A higher score indicates greater depression. A negative change score indicates improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale Total Score at Week 6
units on a scalePlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mg
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale Total Score at Week 6-11.1 ± 0.9-13.0 ± 0.9-15.1 ± 0.8-13.7 ± 0.9
Statistical analysis
  • Placebo vs Cariprazine 0.75 mg · Repeated measures mixed-effects model · p = 0.1292 (The analysis included treatment group, pooled study center, visit, and treatment-group-by-visit interaction as fixed effects and the baseline value and baseline value-by-visit interaction as covariates.) · Mean difference (final values): -1.9 · 95% CI -4.3 to 0.5Cariprazine 0.75 mg vs Placebo
  • Placebo vs Cariprazine 1.5 mg · Repeated measures mixed-effects model · p = 0.0010 (The analysis included treatment group, pooled study center, visit, and treatment-group-by-visit interaction as fixed effects and the baseline value and baseline value-by-visit interaction as covariates.) · Mean difference (final values): -4.0 · 95% CI -6.3 to -1.6Cariprazine 1.5 mg vs Placebo
  • Placebo vs Cariprazine 3.0 mg · Repeated measures mixed-effects model · p = 0.0374 (The analysis included treatment group, pooled study center, visit, and treatment-group-by-visit interaction as fixed effects and the baseline value and baseline value-by-visit interaction as covariates.) · Mean difference (final values): -2.5 · 95% CI -4.9 to -0.1Cariprazine 3.0 mg vs Placebo
SecondaryChange From Baseline in the Clinical Global Impressions-Severity Total Score at Week 6

The Clinical Global Impressions-Severity scale is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The participant is rated on a scale from 1 to 7 with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A higher score indicates greater illness. A negative change score indicates improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Clinical Global Impressions-Severity Total Score at Week 6
units on a scalePlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mg
Change From Baseline in the Clinical Global Impressions-Severity Total Score at Week 6-1.0 ± 0.1-1.1 ± 0.1-1.4 ± 0.1-1.3 ± 0.1
Statistical analysis
  • Placebo vs Cariprazine 0.75 mg · Repeated measures mixed-effects model · p = 0.3025 · Mean difference (final values): -0.1 · 95% CI -0.4 to 0.1Cariprazine 0.75 mg vs Placebo
  • Placebo vs Cariprazine 1.5 mg · Repeated measures mixed-effects model · p = 0.0044 · Mean difference (final values): -0.4 · 95% CI -0.6 to -0.2Cariprazine 1.5 mg vs Placebo
  • Placebo vs Cariprazine 3.0 mg · Repeated measures mixed-effects model · p = 0.0489 · Mean difference (final values): -0.3 · 95% CI -0.5 to -0.0Cariprazine 3.0 mg vs Placebo

Adverse events

Collected over Adverse Events were collected and recorded from the time the participant signs the informed consent form until 30 days after the last dose of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/145 (0%)5/145 (3.4%)42/145 (29%)
Cariprazine 0.75 mg0/141 (0%)1/141 (0.7%)43/141 (30.5%)
Cariprazine 1.5 mg0/146 (0%)2/146 (1.4%)51/146 (34.9%)
Cariprazine 3.0 mg0/146 (0%)2/146 (1.4%)56/146 (38.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mg
DepressionPsychiatric disorders1/1451/1410/1460/146
HemiparesisNervous system disorders1/1450/1410/1460/146
ManiaPsychiatric disorders1/1450/1410/1460/146
Suicidal ideationPsychiatric disorders1/1450/1410/1460/146
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/1450/1410/1460/146
FallInjury, poisoning and procedural complications0/1450/1411/1461/146
Lower limb fractureInjury, poisoning and procedural complications0/1450/1410/1461/146
InjuryInjury, poisoning and procedural complications0/1450/1411/1460/146
Vertigo CNS originNervous system disorders0/1450/1410/1461/146
HypomaniaPsychiatric disorders0/1450/1411/1460/146
Most frequent other events
Most frequent other events
EventPlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mg
AkathisiaNervous system disorders2/1454/1417/14621/146
HeadacheNervous system disorders17/14511/14111/14610/146
InsomniaPsychiatric disorders12/14516/14110/14617/146
NauseaGastrointestinal disorders7/14512/14112/14612/146
DiarrhoeaGastrointestinal disorders10/1452/1419/1463/146
SomnolenceNervous system disorders7/1456/14110/14610/146
RestlessnessPsychiatric disorders5/1454/1414/1469/146

Baseline characteristics

Safety population: All randomized participants who received at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(years)PlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mgTotal
Mean43.6 ± 12.040.1 ± 11.240.9 ± 11.442.8 ± 10.841.9 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mgTotal
Female89919288360
Male56505458218
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mgTotal
Hispanic or Latino1213111248
Not Hispanic or Latino133128135134530
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mgTotal
White110111109113443
Black or African-American30263026112
Asian11204
American Indian or Alaska Native21137
Other224412
Weight
Weight(kg)PlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mgTotal
Mean79.98 ± 17.0880.81 ± 18.3681.43 ± 16.7981.45 ± 17.8680.92 ± 17.49
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mgTotal
Mean27.81 ± 5.2728.42 ± 5.7128.44 ± 5.3928.28 ± 5.6428.24 ± 5.50
Waist circumference
Waist circumference(cm)PlaceboCariprazine 0.75 mgCariprazine 1.5 mgCariprazine 3.0 mgTotal
Mean91.40 ± 14.2493.32 ± 15.4593.38 ± 14.5593.24 ± 15.4092.83 ± 14.90
08

Study locations

88 sites
  • Forest Investigative Site 021
    Birmingham, Alabama 35216, United States
  • Forest Investigative Site 017
    Springdale, Arkansas 72764, United States
  • Forest Investigative Site 030
    Beverly Hills, California 90210, United States
  • Forest Investigative Site 018
    Cerritos, California 90703, United States
  • Forest Investigative Site 028
    Costa Mesa, California 92626, United States
  • Forest Investigative Site 015
    Oceanside, California 92056, United States
  • Forest Investigative Site 011
    Temecula, California 92591, United States
  • Forest Investigative Site 012
    Jacksonville, Florida 32256, United States
  • Forest Investigative Site 035
    Orlando, Florida 32806, United States
  • Forest Investigative Site 013
    Winter Park, Florida 32789, United States
  • Forest Investigative Site 038
    Atlanta, Georgia 30308, United States
  • Forest Investigative Site 005
    Atlanta, Georgia 30328, United States
  • Forest Investigative Site 029
    Chicago, Illinois 60640, United States
  • Forest Investigative Site 024
    Indianapolis, Indiana 46260, United States
  • Forest Investigative Site 031
    Prairie Village, Kansas 66206, United States
  • Forest Investigative Site 041
    Lake Charles, Louisiana 70629, United States
  • Forest Investigative Site 040
    Shreveport, Louisiana 71104, United States
  • Forest Investigative Site 039
    Flowood, Mississippi 39232, United States
  • Forest Investigative Site 026
    Creve Coeur, Missouri 63141, United States
  • Forest Investigative Site 037
    Las Vegas, Nevada 89102, United States
  • Forest Investigative Site 023
    Cherry Hill, New Jersey 08002, United States
  • Forest Investigative Site 014
    Marlton, New Jersey 08053, United States
  • Forest Investigative Site 006
    Albuquerque, New Mexico 87109, United States
  • Forest Investigative Site 003
    Brooklyn, New York 11214, United States
  • Forest Investigative Site 025
    New York, New York 10021, United States
  • Forest Investigative Site 036
    Canton, Ohio 44718, United States
  • Forest Investigative Site 008
    Dayton, Ohio 45417, United States
  • Forest Investigative Site 042
    Salem, Oregon 97301, United States
  • Forest Investigative Site 009
    Allentown, Pennsylvania 18104, United States
  • Forest Investigative Site 010
    Media, Pennsylvania 19063, United States
  • Forest Investigative Site 033
    Lincoln, Rhode Island 02865, United States
  • Forest Investigative Site 019
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site 007
    Dallas, Texas 75231, United States
  • Forest Investigative Site 016
    Houston, Texas 77008, United States
  • Forest Investigative Site 027
    Houston, Texas 77054, United States
  • Forest Investigative Site 020
    San Antonio, Texas 78229, United States
  • Forest Investigative Site 043
    Bellevue, Washington 98007, United States
  • Forest Investigative Site 032
    Seattle, Washington 98104, United States
  • Forest Investigative Site 311
    Kardzhali, 6600, Bulgaria
  • Forest Investigative Site 307
    Kazanlak, 6100, Bulgaria
  • Forest Investigative Site 310
    Lovech, 5500, Bulgaria
  • Forest Investigative Site 313
    Novi Iskar, 1282, Bulgaria
  • Forest Investigative Site 309
    Pazardzhik, 4400, Bulgaria
  • Forest Investigative Site 302
    Pleven, 5800, Bulgaria
  • Forest Investigative Site 301
    Plovdiv, 4002, Bulgaria
  • Forest Investigative Site 305
    Sofia, 1431, Bulgaria
  • Forest Investigative Site 306
    Sofia, 1431, Bulgaria
  • Forest Investigative Site 308
    Tsarev Brod, 9747, Bulgaria
  • Forest Investigative Site 312
    Tserova Koria, 5047, Bulgaria
  • Forest Investigative Site 102
    Kelowna, British Columbia V1Y 1Z9, Canada
  • Forest Investigative Site 103
    Penticton, British Columbia V2A 4M4, Canada
  • Forest Investigative Site 101
    Chatham, Ontario N7L 5L9, Canada
  • Forest Investigative Site 804
    Barranquilla, Colombia
  • Forest Investigative Site 806
    Barranquilla, Colombia
  • Forest Investigative Site 803
    Bogota, Colombia
  • Forest Investigative Site 805
    Bogotá, Colombia
  • Forest Investigative Site 808
    Bogotá, Colombia
  • Forest Investigative Site 807
    Pereira, Colombia
  • Forest Investigative Site 601
    Arkhangelsk, 163530, Russian Federation
  • Forest Investigative Site 605
    Moscow, 107076, Russian Federation
  • Forest Investigative Site 607
    Moscow, 115522, Russian Federation
  • Forest Investigative Site 611
    Moscow, 117152, Russian Federation
  • Forest Investigative Site 619
    Moscow, 127083, Russian Federation
  • Forest Investigative Site 603
    Nizhniy Novgorod, 603152, Russian Federation
  • Forest Investigative Site 612
    Saint-Petersburg, 199034, Russian Federation
  • Forest Investigative Site 617
    Samara, 443016, Russian Federation
  • Forest Investigative Site 616
    Saratov, 410028, Russian Federation
  • Forest Investigative Site 604
    St. Petersburg, 190005, Russian Federation
  • Forest Investigative Site 606
    St. Petersburg, 190121, Russian Federation
  • Forest Investigative Site 602
    St. Petersburg, 191119, Russian Federation
  • Forest Investigative Site 613
    St. Petersburg, 191119, Russian Federation
  • Forest Investigative Site 608
    St. Petersburg, 192019, Russian Federation
  • Forest Investigative Site 615
    St. Petersburg, 192019, Russian Federation
  • Forest Investigative Site 609
    Tomsk, 634014, Russian Federation
  • Forest Investigative Site 618
    Tver, 170005, Russian Federation
  • Forest Investigative Site 610
    Voronezh, 394052, Russian Federation
  • Forest Investigative Site 707
    Kerch, AR Crimea 98310, Ukraine
  • Forest Investigative Site 709
    Kherson, Vil. Stepanivka 73488, Ukraine
  • Forest Investigative Site 714
    Donetsk, 83008, Ukraine
  • Forest Investigative Site 712
    Ivano-Frankivsk, 76014, Ukraine
  • Forest Investigative Site 703
    Kharkiv, 61068, Ukraine
  • Forest Investigative Site 704
    Kharkiv, 61068, Ukraine
  • Forest Investigative Site 702
    Kharkiv, 61103, Ukraine
  • Forest Investigative Site 708
    Kyiv, 02660, Ukraine
  • Forest Investigative Site 701
    Kyiv, 04080, Ukraine
  • Forest Investigative Site 710
    Odesa, 65014, Ukraine
  • Forest Investigative Site 706
    Simferopol, 95006, Ukraine
  • Forest Investigative Site 705
    Vinnytsia, 21005, Ukraine
09

References and documents

Publications

  • Vieta E, Calabrese JR, Whelan J, Tohen M, Earley WR. The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial. Curr Med Res Opin. 2021 Sep;37(9):1635-1643. doi: 10.1080/03007995.2021.1932446. Epub 2021 Jun 7. PubMed 34034612 ↗
  • Citrome L, Yatham LN, Patel MD, Barabassy A, Hankinson A, Earley WR. Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression. J Affect Disord. 2021 Jun 1;288:191-198. doi: 10.1016/j.jad.2021.03.076. Epub 2021 Mar 31. PubMed 33915374 ↗
  • Thase ME, Harrington A, Calabrese J, Montgomery S, Niu X, Patel MD. Evaluation of MADRS severity thresholds in patients with bipolar depression. J Affect Disord. 2021 May 1;286:58-63. doi: 10.1016/j.jad.2021.02.043. Epub 2021 Feb 20. PubMed 33677183 ↗
  • Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W. Broad Efficacy of Cariprazine on Depressive Symptoms in Bipolar Disorder and the Clinical Implications. Prim Care Companion CNS Disord. 2020 Sep 17;22(5):20m02611. doi: 10.4088/PCC.20m02611. PubMed 32942346 ↗
  • Earley WR, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, Calabrese JR, Yatham LN. A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. J Affect Disord. 2020 Feb 15;263:386-395. doi: 10.1016/j.jad.2019.11.098. Epub 2019 Nov 22. PubMed 31969269 ↗
  • Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Nemeth G, Vieta E, Calabrese JR, Yatham LN. An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression. Am J Psychiatry. 2016 Mar 1;173(3):271-81. doi: 10.1176/appi.ajp.2015.15020164. Epub 2015 Nov 6. PubMed 26541814 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Jan 2014, 29 months.

Results were first posted in May 2018, 4 years 3 months after primary completion. A results delay was requested in Feb 2015.

Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2011
First posted
Jul 18, 2011
StartActual
Jul 26, 2011
Primary completionActual
Jan 10, 2014
CompletionActual
Jan 10, 2014
Results delay requested
Feb 27, 2015
Results first posted
May 1, 2018
Last update
May 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01396447
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Jul 18, 2011
Start date
Jul 26, 2011
Primary completion
Jan 10, 2014
Completion
Jan 10, 2014
Results posted
May 1, 2018
Last update
May 1, 2018

Study contacts

Willie Earley, MD
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion